NorthWest Biotherapeutics Inc (NWBO)

[jondoeuk]

Now Moderna supposedly knows how to pick the antigens because it had a flashy early phase 2 with Keytruda in Melanoma.

The trial was randomised. In addition, MRNA has presented data on its bioinformatics algorithm https://aacrjournals.org/cancerres/article/80/16_Supplement/6539/644669/Abstract-6539-Bioinformatics-algorithm-of-mRNA

Good luck to them I say, but Melanoma is an immunogenic (hot tumor) cancer with many many targets.

Well, there is data in melanoma suggesting an immunodominant response https://aacrjournals.org/cancerres/article/80/16_Supplement/NG11/645332/Abstract-NG11-Landscape-analysis-of-neoepitope https://jitc.bmj.com/content/10/Suppl_2/A135

As for other types, GRTS's personalised (neoantigen) vaccine has shown encouraging clinical data in patients with metastatic MSS CRC. Also, BNTX's (again, neoantigen) in patients with (resected) pancreatic https://www.globenewswire.com/news-release/2022/06/05/2456347/0/en/Positive-Phase-1-Data-from-mRNA-based-Individualized-Neoantigen-Specific-Immunotherapy-in-Patients-with-Resected-Pancreatic-Cancer-presented-at-ASCO.html